Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
The Boeing Company
BA·Industrials
C ★★Sell
Current$171.55
Oct 31, 2026

Boeing's aerospace duopoly, record backlog, and profitable services franchise support a potential operational turnaround, but persistent production constraints, high leverage, and weak recurring cash generation leave the recovery vulnerable to further delays.

Score
56
The Cheesecake Factory Incorporated
CAKE·Consumer Discretionary
C ★★Sell
Current$113.12
Oct 30, 2026

Cheesecake Factory's powerful flagship brand and improving restaurant margins support earnings growth, but elevated valuation multiples and uncertainty around the durability of exceptional comparable sales limit investment appeal.

Score
56
NIKE, Inc.
NKE·Consumer Discretionary
D ★Strong Sell
Current$32.09
Oct 2, 2026

NIKE's global brand and historically low valuation create turnaround upside, but high-single-digit FY2027 revenue decline, China weakness and falling cash flow make the recovery too uncertain today.

Score
56
RH
RH·Consumer Discretionary
D ★Strong Sell
Current$134.17
Sep 15, 2026

RH has a differentiated luxury-design brand with real upside if RH Estates and global expansion restore earnings growth, but heavy leverage, housing-cycle exposure and unproven returns on its global push keep risk-reward unattractive.

Score
56
Bullish
BLSH·Technology
C ★★Sell
Current$19.07
Nov 21, 2026

Bullish could become an integrated leader in institutional digital asset and tokenized securities infrastructure, but substantial acquisition dilution, financing obligations, and uncertain recurring earnings constrain shareholder returns.

Score
55
QXO, Inc.
QXO·Industrials
C ★★Sell
Current$12.60
Nov 15, 2026

QXO offers substantial consolidation-driven growth and procurement synergies in North American building-products distribution, but heavy acquisition financing, dilution and weak cash conversion threaten common-shareholder returns.

Score
55
Ionis Pharmaceuticals, Inc.
IONS·Healthcare
C ★★Sell
Current$28.33
Nov 12, 2026

Ionis has a differentiated RNA therapeutics platform, expanding approved-drug portfolio and valuable pipeline, but weak TRYNGOLZA adoption, substantial cash burn and uncertain profitability undermine its near-term investment appeal.

Score
55
IDEAYA Biosciences, Inc.
IDYA·Healthcare
C ★★Sell
Current$32.03
Nov 10, 2026

IDEAYA Biosciences could create substantial value through darovasertib approval and a differentiated precision-oncology pipeline, but persistent cash burn, dilution, and uncertain commercialization economics weaken the current investment case.

Score
55
TeraWulf Inc.
WULF·Financials
C ★★Sell
Current$11.37
Nov 9, 2026

TeraWulf offers substantial long-term growth potential through contracted AI data center infrastructure, but heavy construction spending, external financing dependence, dilution, and demanding valuation undermine its near-term investment appeal.

Score
55
10x Genomics, Inc.
TXG·Healthcare
C ★★Sell
Current$59.28
Nov 8, 2026

10x Genomics could benefit from the structural expansion of spatial and single-cell biology, but weak consolidated growth, recurring operating losses, dilution, and an expensive valuation limit its investment appeal.

Score
55
Materion Corporation
MTRN·Materials
C ★★Sell
Current$186.11
Nov 7, 2026

Materion benefits from specialized semiconductor and aerospace materials demand, record backlog, and improving cash generation, but demanding valuation and cyclical operating risks weaken the investment case.

Score
55
BioNTech SE
BNTX·Healthcare
C ★★Sell
Current$85.86
Nov 6, 2026

BioNTech's substantial cash reserves and advanced oncology pipeline offer meaningful long-term upside, but declining vaccine revenue, persistent losses, and uncertain clinical commercialization limit near-term investment appeal.

Score
55